Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cells and IL-2 in Recurrent Ovarian and Breast Cancer
NCT01105650Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2010
- Primary completion
- Apr 2014
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic natural killer cells in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), breast cancer, sponsored by Masonic Cancer Center. Started Jul 2010; status: completed.
02
Drugs
allogeneic natural killer cells
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)breast cancer
Beyond the preview
Go deeper on NCT01105650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01105650.